Article Information
History
- July 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jose Mateus1,
- Jennifer M. Dan1,2,
- Zeli Zhang1,
- Carolyn Rydyznski Moderbacher1,
- Marshall Lammers1,
- Benjamin Goodwin1,
- Alessandro Sette1,2,†,
- Shane Crotty1,2,† and
- Daniela Weiskopf1,†
- 1Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA
- 2Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA
- ↵†Corresponding authors: alex{at}lji.org (A.S.), shane{at}lji.org (S.C.), daniela{at}lji.org (D.W.)
Posted July 05, 2021.
Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory
